Trial Profile
A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Rineterkib (Primary)
- Indications Colon cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis; Novartis Pharmaceuticals
- 31 May 2020 Results assessing safety and tolerability of LTT462 in advanced solid tumors harboring MAPK pathway alterations presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 15 Aug 2019 Status changed from completed to discontinued.
- 10 May 2019 This trial has been Discontinued in Netherlands